

Erratum

Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma: Am J Cancer Res. 2019; 9(3): 546-561

Xiwei Ding^{1*}, Yiyang Zhang^{2*}, Tianlu Huang^{1*}, Guifang Xu¹, Chunyan Peng¹, Gang Chen³, Bo Kong^{1,4}, Helmut Friess⁴, Shanshan Shen¹, Ying Lv¹, Lewis R Roberts⁵, Lei Wang¹, Xiaoping Zou²

¹Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu, China; ²Department of Gastroenterology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing 210008, Jiangsu, China; ³Division of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China; ⁴Department of Surgery, Technical University of Munich, Munich 80333, Germany; ⁵Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, Rochester 55905, MN, US. *Equal contributors.

Received September 23, 2023; Accepted October 12, 2023; Epub November 15, 2023; Published November 30, 2023

In this article, we discovered an unintentional error that the Combination Index (CI) image of ABC294640 with Obatoclax in HCCC9810 cells in **Figure 4B** was misplaced during the preparation of figures using GraphPad Prism 6.0 software. The data that was used to calculate the Combination Index using CompuSyn software was correctly presented just above the Combination Index figure (Cell viability curve of HCCC9810 with different inhibitors treatment in **Figure 4B**).

Therefore, we would like to publish this Erratum to reflect this change. These corrections do not change the results or conclusions

of this paper. We sincerely apologize for inconvenience caused by unintentional negligence.

The corrected **Figure 4** is as follows.

Address correspondence to: Xiaoping Zou, Department of Gastroenterology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, No. 321 Zhongshan Road, Nanjing 210008, Jiangsu, China. Tel: +86-25-83106666-61321; E-mail: zouxp@nju.edu.cn; zxpjdt@126.com

Effect of ABC294640 in cholangiocarcinoma




Figure 4. ABC294640 acts synergistically with BH3-mimetics in inhibiting cholangiocarcinoma cell growth. A. RBE, HCCC9810 and HuH28 cells were treated with various concentrations of ABC294640 or ABT-263 alone or their combination for 72 h, then the cell viability was analyzed by CCK-8 assay. The results are presented as mean ± SEM from 3-4 independent experiments. The combination index (CI) was determined using the Chou-Talalay Method. CI < 1 indicates that the interaction between ABC294640 and ABT-263 was synergistic. B. RBE, HCCC9810 and HuH28 cells were treated with various concentrations of ABC294640 or Obatoclox alone or their combination for 72 h, then the cell viability was analyzed by CCK-8 assay. The results are presented as mean ± SEM from 3-4 independent experiments. CI was determined using the Chou-Talalay Method. CI < 1 indicates that the interaction between ABC294640 and Obatoclox was synergistic.